A middleman at the heart of America’s insulin-pricing scandal just agreed to cap members’ insulin at $25 a month — and to change the rebate machinery beneath it. What the CVS Caremark settlement with the FTC really does, and what it doesn’t.
Health news explainer.
For years, the price of insulin in the United States has been a scandal hiding in plain sight: a nearly century-old drug, cheap to make, that some patients have rationed because they couldn’t afford it. In July 2026, one of the middlemen at the center of that story agreed to change how it does business — and the headline number is one patients will notice. Here is what the CVS Caremark settlement with the Federal Trade Commission actually does.
The $25 cap
The most concrete change: under the settlement, CVS Caremark is required to cap members’ insulin costs at $25 a month, as reported by outlets including CNBC and confirmed in the FTC’s announcement. For a person with diabetes who depends on insulin to stay alive, a predictable $25 monthly cost is not a policy abstraction — it is the difference between filling a prescription and stretching it.
Who is CVS Caremark, and why were they sued?
This is where the story gets to the real problem. CVS Caremark is a pharmacy benefit manager, or PBM — one of the “Big Three” middlemen that sit between drug makers, insurers, and pharmacies, negotiating which drugs are covered and at what price. The FTC’s 2024 lawsuit accused the largest PBMs, including Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx, of building a rebate system that, the agency argued, pushed insulin list prices up rather than down. In plain terms: the complaint was that the incentives rewarded higher sticker prices, and patients whose costs were tied to those stickers paid the price.
What else the settlement changes
The $25 cap is the headline, but the structural terms may matter more over time. According to legal summaries of the deal, Caremark agreed to promote passing rebates through to patients at the point of sale as a standard option, to delink the compensation it earns from a drug’s list price, and to move toward acquisition-based reimbursement for independent retail pharmacies. Each of those attacks a different gear in the machine that critics say inflates prices — the goal being that the rebate game stops rewarding high list prices in the first place.
Part of a bigger shift
Caremark is not the first to fold. It is the second of the three big PBMs to settle with the FTC in this case, following Express Scripts earlier in 2026, per reporting from Fierce Healthcare. That pattern is the real signal: the pressure on the PBM model is now regulatory and sustained, not rhetorical. For a system long criticized as an opaque black box, a second major player accepting binding changes suggests the box is being pried open.
The honest caveats
Two notes of realism. First, a settlement is not an admission that fixes everything; companies frame these agreements as advancing transparency they were already pursuing, and the practical effect depends on how the terms are implemented and enforced. Second, insulin affordability has many moving parts — manufacturer list prices, state laws, federal caps for some patients, and insurance design — so one PBM’s cap does not, by itself, solve the whole problem for everyone. But a guaranteed low monthly cost for affected members, plus structural changes to how rebates work, is a concrete improvement in a fight that has dragged on far too long.
Why it matters
Millions of people depend on insulin, and the cost of it has been a recurring source of fear and rationing. A binding $25 cap and a set of rules aimed at the pricing machinery beneath it is exactly the kind of change that shows up in real households, not just in press releases. It also puts the last of the big three middlemen on notice. For anyone who has watched drug-pricing debates produce more heat than relief, this is a rare case of relief with a number attached.
General information, not medical or financial advice. Coverage, caps, and eligibility vary by plan and change over time; check your own plan’s terms. Sources are linked above.
